Evidence mapPaperPMID 32178672Full record

ArticleLipids in health and disease2020

Dyslipidemia and cardiovascular disease risk among the MASHAD study population.

Mahshad Hedayatnia, Zahra Asadi, Reza Zare-Feyzabadi, Mahdiyeh Yaghooti-Khorasani, Hamideh Ghazizadeh, Roshanak Ghaffarian-Zirak, Abolfazl Nosrati-Tirkani, Maryam Mohammadi-Bajgiran, Mohadese Rohban, Fatemeh Sadabadi and 10 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 176 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 8 pooled it
38.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06674044 completedstarted 2023, after this paper: background citation

Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population

Ran2023Enrolled100Registered outcomes3Posted comparisons0ConditionsHyperlipidemiasArmsAtorvastatin
Open the trial in the graph
NCT07148037 completedstarted 2024, after this paper: background citation

Effect of SLC01B1 (rs4149056) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population

Ran2024Enrolled150Registered outcomes3Posted comparisons0ConditionsHyperlipidemiasArmsAtorvastatin
Open the trial in the graph
3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 8 syntheses or guidelines pooled it, 366 citations in OpenAlex.

  1. Effects ofNutrients · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Mahshad HedayatniaDepartment of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Zahra AsadiDepartment of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Reza Zare-FeyzabadiMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mahdiyeh Yaghooti-KhorasaniMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamideh GhazizadehStudent Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
Roshanak Ghaffarian-ZirakMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abolfazl Nosrati-TirkaniMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Maryam Mohammadi-BajgiranMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohadese RohbanMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Fatemeh SadabadiMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid-Reza RahimiMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Marzieh GhalandariMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad-Seddigh GhaffariFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Asa YousefiFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Elnaz PouresmaeiliFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad-Reza BesharatlouFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohsen MoohebatiCardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon A FernsDivision of Medical Education, Brighton & Sussex Medical School, Falmer, Brighton, Sussex, UK.
Habibollah EsmailySocial Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Esmailyh@mums.ac.ir.
Majid Ghayour-MobarhanMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. ghayourm@mums.ac.ir.ORCID http://orcid.org/0000-0002-1081-6754
Mashhad University of Medical Sciences · IRBrighton and Sussex Medical School · GB

Funding

Mashhad University of Medical Sciences 85134
6 · The paper itself

Abstract

introductionDyslipidemia may be defined as increased levels of serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), or a decreased serum high-density lipoprotein cholesterol (HDL-C) concentration. Dyslipidemia is an established risk factor for cardiovascular disease (CVD). We aimed to investigate the association of dyslipidemia and CVD events among a population sample from Mashhad, in northeastern Iran. MATERIAL AND

methodsThis prospective cohort study comprised a population of 8698 men and women aged 35-65 years who were recruited from the Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) study. Socioeconomic and demographic status, anthropometric parameters, laboratory evaluations, lifestyle factors, and medical history were gathered through a comprehensive questionnaire and laboratory and clinical assessment for all participants. Cox regression model and 95% confidence interval (CI) were used to evaluate the association of dyslipidemia and its components with CVD incidence.

resultsAfter 6 years of follow-up, 233 cases of CVD (including 119 cases of unstable angina [US], 74 cases of stable angina [SA], and 40 cases of myocardial infarction [MI]) were identified in the study population. Unadjusted baseline serum LDL-C, TC, and TG levels were positively associated with the risk of total CVD events among the entire population (HR: 1.54, 95% CI: 1.19-2; P-value< 0.01; HR: 1.53; 95% CI: 1.18-1.98; P < 0.01; HR: 1.57; 95% CI: 1.27-2.03; P < 0.01, respectively). However, after adjusting for confounding factors (age, body mass index [BMI], family history of CVD, smoking status [non-smoker, ex-smoker and current smoker], lipid lowering drug treatment, anti-hypertensive drug treatment, hypertension, healthy eating index [HEI], total energy intake, and presence of diabetes mellitus), a significant direct association only remained between TC and MI risk in men (HR: 2.71; 95%CI: 1.12-6.57; P-value< 0.05).

conclusionIn the present study, TC baseline level was significantly associated with the risk of MI among men.

Indexed as

AdultAngina, StableAngina, UnstableCardiovascular DiseasesCholesterol, HDLCholesterol, LDLDyslipidemiasFemaleHumansMaleMiddle AgedMyocardial InfarctionProspective StudiesRisk FactorsTriglyceridesCholesterol, HDLCholesterol, LDLTriglyceridesCardiovascular diseaseDyslipidemiaMyocardial infarctionStable anginaTotal cholesterolUnstable angina

Identifiers

PMID32178672
PMCPMC7075010
OpenAlexW3012162348

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.